Life Sciences Venture Fund aMoon Invests $5 Million in Cancer Drug Company
NanoGhosts turns stem cells into a drug delivery system that specifically targets cancerous tumors
Hagar Ravet | 17:22 24.12.2019
Israel-based life sciences, healthcare, and technology venture capital firm aMoon, together with an unnamed private investor, invested $5 million in cancer drug startup NanoGhosts, aMoon told Calcalist. This is NanoGhosts’s first investment. Founded earlier this year by Marcelle Machluf, a researcher at Israeli research university the Technion Israel Institute of Technology, NanoGhosts’ technology is based on its founder’s research, that the Technion's commercial unit has patented in the U.S. and Europe. Technion statements. AMoon was founded in 2016 by Yair Schindel, the former CEO of an Israeli government agency in charge of pushing forward digital initiatives, and Marius Nacht, the co-founder of firewall pioneer Check Point Software Technologies Ltd. Its first fund was backed exclusively by Nacht. AMoon's portfolio companies include gut microbiome analysis company DayTwo Ltd., cancer diagnosis startup Ibex Medical Analytics Ltd., and medical analytics company Zebra Medical Vision Ltd.